Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Martee L. Hensley, John A. Blessing, Koen DeGeest, Ovadia Abulafia, Peter G. Rose, Howard D. Homesley

Research output: Contribution to journalArticlepeer-review

182 Scopus citations

Fingerprint Dive into the research topics of 'Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences